Regeneron Pharmaceuticals, Inc.’s recently made public that its Director RYAN ARTHUR F unloaded Company’s shares for reported $0.1 million on Oct 01 ’24. In the deal valued at $1048.78 per share,100 shares were sold. As a result of this transaction, RYAN ARTHUR F now holds 17,582 shares worth roughly $17.42 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, McCourt Marion sold 1,000 shares, generating $1,054,060 in total proceeds. Upon selling the shares at $1054.06, the EVP Commercial now owns 12,931 shares.
Before that, MARION E MCCOURT bought 1,000 shares. Regeneron Pharmaceuticals, Inc. shares valued at $1,054,060 were divested by the Officer at a price of $1054.06 per share.
Leerink Partners downgraded its Regeneron Pharmaceuticals, Inc. [REGN] rating to a Market perform from a an Outperform in a research note published on September 24, 2024; the price target was decreased to $1077 from $1175. A number of analysts have revised their coverage, including Bernstein’s analysts, who began to cover the stock in mid March with a ‘”an Outperform”‘ rating. RBC Capital Mkts also remained covering REGN and has increased its forecast on January 12, 2024 with a “an Outperform” recommendation from previously “Sector perform” rating. Deutsche Bank started covering the stock on November 09, 2023. It rated REGN as “a Hold”.
Price Performance Review of REGN
On Friday, Regeneron Pharmaceuticals, Inc. [NASDAQ:REGN] saw its stock fall -0.76% to $990.68. Over the last five days, the stock has lost -2.46%. Regeneron Pharmaceuticals, Inc. shares have risen nearly 12.80% since the year began. Nevertheless, the stocks have risen 19.93% over the past one year. While a 52-week high of $1211.20 was reached on 08/27/24, a 52-week low of $769.19 was recorded on 01/02/24. SMA at 50 days reached $1,108.51, while 200 days put it at $1,013.24.
Levels Of Support And Resistance For REGN Stock
The 24-hour chart illustrates a support level at 986.07, which if violated will result in even more drops to 981.46. On the upside, there is a resistance level at 998.99. A further resistance level may holdings at 1,007.30. The Relative Strength Index (RSI) on the 14-day chart is 30.09, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -13.22, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 98.73%. Stochastics %K at 9.60% indicates the stock is a buying.
How much short interest is there in Regeneron Pharmaceuticals, Inc.?
A steep rise in short interest was recorded in Regeneron Pharmaceuticals, Inc. stocks on 2024-09-30, dropping by -0.37 million shares to a total of 1.73 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-30 was 2.1 million shares. There was a decline of -21.24%, which implies that there is a negative sentiment for the stock.
